<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5339">
  <stage>Registered</stage>
  <submitdate>14/01/2016</submitdate>
  <approvaldate>14/01/2016</approvaldate>
  <nctid>NCT02657694</nctid>
  <trial_identification>
    <studytitle>Reviewing DAA Efficacy Managing Patient Treatment In Online Neighbourhoods</studytitle>
    <scientifictitle>Reviewing DAA Efficacy Managing Patient Treatment In Online Neighbourhoods</scientifictitle>
    <utrn />
    <trialacronym>REDEMPTION</trialacronym>
    <secondaryid>REDEMPTION</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis C</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Sofosbuvir+Ledipasvir
Treatment: drugs - Sofosbuvir+Daclatasvir
Treatment: drugs - Sofosbuvir+Velpatasvir

Sofosbuvir+Ledipasvir - Following patients treating with Sofosbuvir+Ledipasvir

Sofosbuvir+Daclatasvir - Following patients treating with Sofosbuvir+Daclatasvir

Sofosbuvir+Velpatasvir - Following patients treating with Sofosbuvir+Velpatasvir


Treatment: drugs: Sofosbuvir+Ledipasvir
DAA medication treatment

Treatment: drugs: Sofosbuvir+Daclatasvir
DAA medication treatment

Treatment: drugs: Sofosbuvir+Velpatasvir
DAA medication treatment

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Sustained Virological Response 4 (SVR4) by Hepatitis C Virus (HVC) RNA Polymerase Chain Reaction (PCR) - Viral load 4 weeks after cessation of treatment as measured by HCV RNA PCR, where SVR is defined as HCV RNA &lt; Lower Limit Of Quantification (LLOQ)</outcome>
      <timepoint>4-7 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Side Effects - Collating common side effects on treatment</outcome>
      <timepoint>3-6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rapid Virological Response (RVR) by HCV RNA PCR - Viral load 4 weeks after starting treatment as measured by HCV RNA PCR</outcome>
      <timepoint>4 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>End Of Treatment (EOT) Response by HCV RNA PCR - Viral load at end of treatment as measured by HCV RNA PCR</outcome>
      <timepoint>3-6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Sustained Virological Response (SVR12) by HCV RNA PCR - Viral load 12 weeks after cessation of treatment as measured by HCV RNA PCR, where SVR is defined as HCV RNA &lt; Lower Limit Of Quantification (LLOQ)</outcome>
      <timepoint>6-12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Quantitative HCV RNA &gt; 100</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>82</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Contraindications to DAA medications</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational [Patient Registry]</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10000</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>30/06/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>TAS</recruitmentstate>
    <hospital>FixHepC - Hobart</hospital>
    <postcode>7004 - Hobart</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>FixHepC</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>REDEMPTION (Reviewing DAA Efficacy Managing Patient Treatment In Online Neighbourhoods) is
      observing and collating the treatment course, safety profile, and outcomes of patients around
      the world who are choosing to self import generic versions of the Direct Acting Antivirals
      Sofosbuvir, Ledipasvir and Daclatasvir from countries like China, India and Bangladesh.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02657694</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>James Freeman, MB,BS,BSc</name>
      <address>ACRRM</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>